Clinical Trials Browser

Triple Negative Breast Neoplasms × pegfilgrastim × Clear all

NCT07525869 2026-04-20

An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy

Phase NA Recruiting

Triple Negative Breast Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Phase 2 Completed

29 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03036488 2025-10-29

MK-3475-522

Phase 3 Completed

1,174 enrolled 1 FDA

Triple Negative Breast Neoplasms

NCT07064018 2025-07-14

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

Phase 1/2 Recruiting

BreastGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT03639948 2024-04-11

NeoPACT

Phase 2 Unknown

120 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02834403 2023-12-15

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Phase 1/2 Completed

37 enrolled 20 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03197935 2023-10-26

IMpassion031

Phase 3 Completed

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Phase 1 Completed

Triple Negative Breast Neoplasms